Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression

Journal of Leukocyte Biology

Volumn 61, Issue 4, 1997, Pages 507-516

  Aruga, Atsushi ^a   Aruga, Etsuko ^a   Cameron, Mark J ^a   Chang, Alfred E ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

interferon ; interleukin 2; tumor reactivity; tumor regression

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; LUNG METASTASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REGRESSION;

EID: 0030915175     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.61.4.507     Document Type: Article

References (37)

1. Chou, T., Chang, A. E., Shu, S. (1988) Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J. Immunol. 140, 2453-2461.
2. Chou, T., Bertera, S., Chang, A. E., Shu, S. (1988) Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J. Immunol. 141, 1775-1781.
3. Ward, B. A., Shu, S., Chou, T., Perry-Lalley, D., Chang, A. E. (1988) Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J. Immunol. 141, 1047-1053.
4. Yoshizawa, H., Sakai, K., Chang, A. E., Shu, S. (1991) Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 134, 473-479.
5. Yoshizawa, H., Chang, A. E., Shu, S. (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147, 729-737.
6. Geiger, J. D., Wagner, P. D., Cameron, M. J., Shu, S., Chang, A. E. (1993) Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother. 13, 153-165.
7. Crossland, K. D., Lee, V. K., Chen, W., Riddell, S. R., Greenberg, P. D., Cheever, M. A. (1991) T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J. Immunol. 146, 4414-4420.
8. Goedegebuure, P. S., Zuber, M., Leonard-Vidal, D. L., Burger, U. L., Cusack, J. C., Chang, M. P., Douville, L. M., Eberlein, T. J. (1994) Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg. Oncol. 3, 79-89.
9. + tumor-infiltrating lymphocytes. J. Exp. Med. 173, 647-658.
10. Aruga, A., Shu, S., Chang, A. E. (1995) Tumor-specific GM-CSF and INF-γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol. Immunother. 41, 317-324.
11. Barth, R. J., Bock, S. N., Mulé, J. J., Rosenberg, S. A. (1990) Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J. Immunol. 144, 1531-1537.
12. + tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res. 50, 2363-2370.
13. Wexler H. (1966) Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst. 36, 641-645.
14. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., Ochoa, A. C. (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258, 1795-1798.
15. Fu, E. J., Arca, M. J., Haim, J. M., Krinock, R., Rado, J., Cameron, M. J., Chang, A. E., Sondak, V. K. (1997) Tumor-induced suppression of antitumor reactivity and depression of TCR expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway. J. Immunother. in press.
16. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C., Reichert, C. M. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492.
17. Grimm, E. A., Robb, R. J., Roth, J. A., Neckers, L. M., Lachman, L. B., Wilson, D. J., Rosenberg, S. A. (1983) Lymphokine-activated killer cell phenomenon. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J. Exp. Med. 158, 1356-1361.
18. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., White, D. E., Steinberg, S. M. (1993) Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85, 622-632.
19. Rosenberg, S. A., Spiess. P., Lafreniere, R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233, 1318-1321.
20. Spiess, P. J., Yang, J. C., Rosenberg, S. A. (1987) In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst. 79, 1067-1075.
21. Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., White, D. E. (1994) Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86, 1159-1166.
22. Goedegebuure, P. S., Douville, L. M., Li, H., Richmond, G. C., Schoof, D. D., Scavone, M., Eberlein, T. J. (1995) Adoptive immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. J. Clin. Oncol. 13, 1939-1949.
23. Chang, A. E., Yoshizawa, H., Sakai, K., Cameron, M. J., Sondak, V. K., Shu, S. (1993) Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53, 1043-1050.
24. Chang, A. E., Aruga, A., Cameron, M. J., Sondak, V. K., Normolle, D. P., Fox, B. A., Shu, S. (1996) Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J. Clin. Oncol., in press.
25. Schwartzentruber, D. J., Hom, S. S., Dadmarz, R., White, D. E., Yannelli, J. R., Steinberg, S. M., Rosenberg, S. A., Topalian, S. L. (1994) In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 12, 1475-1483.
26. Chang, A. E., Shu, S., Chou, T., Lafreniere, R., Rosenberg, S. A. (1986) Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res. 46, 3426-3430.
27. Shu, S., Fonseca, L. S., Kato, H., Zbar, B. (1983) Mechanisms of immunological eradication of a syngeneic guinea pig tumor: participation of a component(s) of recipient origin in the expression of systemic adoptive immunity. Cancer Res. 43, 2637-2643.
28. Mulé, J. J., Rosenstein, M., Shu, S., Rosenberg, S. A. (1985) Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). Cancer Res. 45, 526-531.
29. Kleinerman, E. S., Knowles, R. D., Lachman, L. B., Gutterman, J. U. (1988) Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. Cancer Res. 48, 2604-2609.
30. Arenzana-Seisdedos, F., Virelizier, J. L., Fiers, W. (1985) Interferons as macrophage-activating factors. Preferential effects of interferon γ on the interleukin 1 secretory potential of fresh or aged human monocytes. J. Immunol. 134, 2444-2448.
31. Hamann, U., Krammer, P. H. (1985) Activation of macrophage tumor cytotoxicity by the synergism of two T cell derived lymphokines: immune interferon (IFN-γ) and macrophage cytotoxicity inducing factor 2 (MCIF2). Eur. J. Immunol. 15, 18-24.
32. Watson, G. A., Lopez, D. M. (1995) Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down regulation of their T cell responses. J. Immunol. 155, 3124-3134.
33. Nestle, F. O., Burg, G., Fah, J., Nickoloff, B. J. (1997) In vivo and in vitro characterization of human tumor associated dendritic cells: deficiency in T cell co-stimulatory molecules and impaired antigen-presenting function. Am. J. Pathol., in press.
34. Tuttle, T. M., McCrady, C. W., Inge, T. H., Salour, M., Bear, H. D. (1993) γ-Interferon plays a key role in T cell induced tumor regression. Cancer Res. 53, 833-839.
35. Cameron, R. B., McIntosh, J. K., Rosenberg, S. A. (1988) Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res. 48, 5810-5817.
36. Weber, J. S., Jay, G., Tanaka, K., Rosenberg, S. A. (1987) Immunotherapy of a murine tumor with interleukin-2. Increased sensitivity after MHC class I gene transfection. J. Exp. Med. 166, 1716-1733.
37. + T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175, 1423-1431.